Tumor-targeting bacteria as immune stimulants - the future of cancer immunotherapy?CRITICAL REVIEWS IN MICROBIOLOGYIF5.12024-02-124OAAI
Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506ACS MEDICINAL CHEMISTRY LETTERSIF42023-10-052OA
Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy ApplicationsPHARMACEUTICALSIF4.82022-02-012OAAI
Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefitCANCER GENE THERAPYIF52021-11-264PREAI
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3PHARMACEUTICALSIF4.82021-11-267OAAI
Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506MOLECULAR CANCER THERAPEUTICSIF5.52021-10-0822OAAI
Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer ImmunotherapyCELLSIF5.22021-04-2472OAAI
Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumoursCANCER GENE THERAPYIF52021-02-0815OAAI
E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applicationsTHERANOSTICSIF13.32020-01-0120OAAI
Hypoxic cell killing by CP-506, a novel hypoxia-activated prodrugRADIOTHERAPY AND ONCOLOGYIF5.32018-04-011OAAI
Hypoxic cell killing by SN36506, a novel hypoxia-activated prodrugRADIOTHERAPY AND ONCOLOGYIF5.32017-05-010OAAI
Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene TherapyCELL CHEMICAL BIOLOGYIF7.22017-03-0162OAAI
Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapyBIOCHEMICAL PHARMACOLOGYIF5.62016-09-0117PREAI
DTP-006: a novel, orally bioavailable hypoxia-activated prodrugRADIOTHERAPY AND ONCOLOGYIF5.32016-04-010OAAI
Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utilityBIOCHEMICAL JOURNALIF4.32015-10-02135PREAI
Pseudomonas aeruginosa NfsB and nitro-CBI-DEI - a promising enzyme/prodrug combination for gene directed enzyme prodrug therapyMOLECULAR CANCERIF33.92013-06-1017OAAI
Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104ABIOCHEMICAL PHARMACOLOGYIF5.62013-04-0148PREAI
Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954BIOCHEMICAL PHARMACOLOGYIF5.62012-09-0129PREAI
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302MOLECULAR CANCER THERAPEUTICSIF5.52012-03-06187OAAI